Avalon GloboCare Reports Laboratory Services MSO Revenue of $14.7 Million and Net Income of $6.3 Million in 2022

Rhea-AI Summary

Avalon GloboCare Corp. (NASDAQ: ALBT) announced a substantial future cash flow expectation due to a 40% profit-sharing agreement with Laboratory Services MSO (LSM). In 2022, LSM reported significant financials: $14.7 million in revenue, $8.1 million gross profit, $2.4 million in operating expenses, and a net income of $6.3 million. Avalon acquired a 40% interest in LSM in February 2023, which enhances its strategic position in the laboratory services market. The company's growth strategy focuses on leveraging LSM's expertise in the fragmented laboratory testing space and aims to generate synergies through targeted acquisitions. Avalon also highlights LSM's strong customer service reputation, rapid turnaround times, and diverse test offerings as key competitive advantages.

Positive

• Anticipated future cash flow from a 40% profit-sharing arrangement with LSM.
• LSM's strong 2022 financial performance: $14.7 million in revenue and $6.3 million net income.
• Strategic acquisition enhances Avalon's market position in laboratory services.
• Focus on leveraging LSM's expertise to achieve significant synergies.

Negative

• Revenue decreased from $18.3 million in 2021 to $14.7 million in 2022, representing a decline of over 20%.
• Net income also fell from $12.3 million in 2021 to $6.3 million in 2022, a decrease of 48%.
• Potential risks associated with the highly fragmented laboratory testing market.

40% Profit Sharing Arrangement with Laboratory Services MSO is Expected to Result in Significant Future Cash Flow to the Company

FREEHOLD, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative cell-based technology, cellular therapy and precision diagnostics, today reported financial results for Laboratory Services MSO, LLC (“LSM”) for the twelve months ended December 31, 2022. In February 2023, Avalon acquired a 40% interest in LSM, a premier clinical diagnostics and reference laboratory.

LSM 2022 Financial Highlights

• Revenue was $14.7 million
• Gross profit was $8.1 million
• Total operating expense was $2.4 million
• Net income was $6.3 million

“We are pleased to report strong financial results and profitability for LSM in 2022, which we believe is further validation of our strategic investment,” stated David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon GloboCare. “LSM offers an extensive test menu, from general bloodwork to anatomic pathology, urine toxicology, pharmacogenomics (PGx) testing and more, with quick turnaround times. Our goal is to continue to grow LSM’s top and bottom line by taking advantage of a unique roll-up opportunity within the highly fragmented market for laboratory testing and services. By targeting laboratories with exceptional performance, a positive revenue track record and niche-market advantage, we believe we can effectively leverage LSM’s experience and infrastructure to achieve significant synergies.”

Headquartered in Costa Mesa, California, LSM provides a broad portfolio of diagnostic tests including drug testing, toxicology, pharmacogenetics, and a broad array of test services, from general bloodwork to anatomic pathology. Specific capabilities include STAT blood testing, qualitative drug screening, genetic testing, urinary testing, sexually transmitted disease testing and more. LSM has a sophisticated and state-of-the-art facility for clinical diagnostics and reference laboratory. It has also developed a premier reputation for customer service satisfaction and fast turnaround time in the industry. LSM has completed over 600,000 tests since inception and currently has two operational locations in California.

About Avalon GloboCare Corp.

Avalon GloboCare Corp. (NASDAQ: ALBT) is a clinical-stage biotechnology company dedicated to developing and delivering innovative, transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients’ growth and development, as well as competitiveness in healthcare and CellTech industry markets. Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and regenerative therapeutics. For more information about Avalon GloboCare, please visit www.avalon-globocare.com.

For the latest updates on Avalon GloboCare’s developments, please follow our twitter at @avalongc_avco

Forward-Looking Statements

Certain statements contained in this press release may constitute “forward-looking statements.” Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact, including statements regarding LSM. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.

Contact Information:
Avalon GloboCare Corp.
4400 Route 9, Suite 3100
Freehold, NJ 07728
PR@Avalon-GloboCare.com 

Investor Relations:
Crescendo Communications, LLC
Tel: (212) 671-1020 Ext. 304
albt@crescendo-ir.com 

(tables follow)

LABORATORY SERVICES MSO, LLC AND AFFILIATES
COMBINED BALANCE SHEETS
				December 31,
				2022		2021
ASSETS
CURRENT ASSETS:
	Cash		$	439,778	$	607,982
	Accounts receivable			4,088,069		3,086,966
	Other current assets			86,277		-
		Total Current Assets		4,614,124		3,694,948
NON-CURRENT ASSETS:
	Operating lease right-of-use assets, net			1,758,063		-
	Finance lease right-of-use assets, net			291,419		-
	Property and equipment, net			14,667		18,667
		Total Non-current Assets		2,064,149		18,667
		Total Assets	$	6,678,273	$	3,713,615
LIABILITIES AND MEMBER'S EQUITY
CURRENT LIABILITIES:
	Accounts payable		$	573,395	$	184,139
	Accrued payroll liability			38,589		42,077
	Operating lease obligation			229,874		-
	Finance lease obligation			112,457		-
		Total Current Liabilities		954,315		226,216
NON-CURRENT LIABILITIES:
	Operating lease obligation - noncurrent portion			1,680,017		-
	Finance lease obligation - noncurrent portion			178,962		-
		Total Non-current Liabilities		1,858,979		-
		Total Liabilities		2,813,294		226,216
	Commitments and Contingencies
MEMBER'S EQUITY				3,864,979		3,487,399
		Total Liabilities and Member's Equity	$	6,678,273	$	3,713,615

LABORATORY SERVICES MSO, LLC AND AFFILIATES
COMBINED STATEMENTS OF INCOME
				For the Year Ended		For the Year Ended
				December 31, 2022		December 31, 2021
REVENUE			$	14,689,747	$	18,278,430
COST OF REVENUE				6,612,268		5,002,674
GROSS PROFIT				8,077,479		13,275,756
OPERATING EXPENSES:
	Selling and marketing expense			1,344,552		480,269
	Professional fees			714,662		375,667
	Other general and administrative expenses			296,704		281,128
		Total Operating Expenses		2,355,918		1,137,064
OPERATING INCOME				5,721,561		12,138,692
OTHER INCOME (EXPENSE)
	Forgiveness of Paycheck Protection Program loan			-		95,000
	Employee Retention Tax Credit			609,634		-
	Other income			11,938		24,330
		Total Other Income, net		621,572		119,330
INCOME BEFORE INCOME TAXES				6,343,133		12,258,022
INCOME TAXES				-		-
NET INCOME			$	6,343,133	$	12,258,022

 

FAQ

What is the significance of the 40% profit-sharing agreement with LSM for ALBT?

The agreement is expected to create substantial future cash flows for Avalon GloboCare, enhancing its revenue potential.

How did Laboratory Services MSO perform financially in 2022?

LSM reported $14.7 million in revenue, $8.1 million in gross profit, and $6.3 million in net income for 2022.

What was Avalon's net income for 2022?

Avalon reported $6.3 million in net income from its 40% interest in LSM for 2022.

What are Avalon's growth strategies in laboratory services?

Avalon aims to grow by targeting high-performing laboratories and leveraging LSM's infrastructure for synergies.

What were Avalon's revenue figures for the previous year?

Avalon's revenue decreased from $18.3 million in 2021 to $14.7 million in 2022.